Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivarmacitinib Combined With Celecoxib Versus Ivarmacitinib Monotherapy in Ankylosing Spondylitis
NCT07894497Phase 4Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Oct 2026
- Primary completion
- Dec 2029
01
Overview
Phase 4, randomised, open-label trial of celecoxib oral solution in ankylosing spondylitis (AS) (2 arms), sponsored by Peking University Third Hospital. Primary endpoint: Assessment of SpondyloArthritis international Society 20% response at 24 weeks. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
celecoxib oral solution
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on NCT07894497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07894497.